Innovating With Intent
At Cullinan Therapeutics, we focus on accelerating the development of high-impact therapies by uniting exceptional scientific expertise, strategic risk-taking, and rigorous decision-making, to improve the lives of those living with autoimmune diseases and cancer.
We believe in Science That Moves: working at a pace that boldly moves science, treatments, and people forward.
OUR APPROACH
targets
high-impact targets
to optimal targets
the optimal target
molecules
to maximize therapeutic potential
in patient-friendly way
We apply our deep understanding of the immune system and leadership in T cell engagers to pursue new treatment options for patients in need. Our team’s complementary experiences in oncology and immunology allow us to rapidly investigate breakthrough scientific opportunities.
Applying a rigorous scientific approach allows us to fully explore the potential of our early discoveries. By conducting definitive “thriller or killer” experiments in early discovery, we advance only the most promising molecules. Programs that meet a high bar for success are rapidly advanced; those that do not meet our threshold criteria are efficiently discontinued. This precise, disciplined approach results in the advancement of programs that maximize therapeutic potential for patients.
SPEED MEETS STRATEGY
Taking definitive action with speed and agility is embedded in who we are. We move science forward to create meaningful advances in autoimmune disease and cancer treatments for the people who need them.
Yet speed alone is not our measure of success — we are equally committed to the integrity, quality, and impact of every trial we conduct. Our clinical development strategy is intentional, designed to accelerate the development of practice-changing medicines through creative, well-designed yet simple trials that serve the needs of people living with these diseases as well as investigators.
Leveraging robust translational research, we develop a deep understanding of the mechanisms of action, dosing parameters, and potential strategies for mitigating toxicity in the early development phase to fully inform our approach in the clinic. For all of our trials, we implement a robust biomarker strategy and a rigorous approach to data analysis to support efficient and thoughtful clinical decision-making.
And we have pride in our partnerships: with an established global network of oncology and rheumatology disease investigators and thought leaders, we are enrolling patients in clinical trials around the world.
Our work in autoimmune diseases
We believe T cell engagers represent the next wave of innovation in autoimmune diseases, as a promising class of biologics that offer the potential for long-lasting immune reset and transformation of care.
COLLABORATING FOR A SHAREd PURPOSE
United with our partners across the healthcare ecosystem, we are accelerating the development of high-impact molecules that will improve the lives of people living with autoimmune diseases and cancer.
